Fig. 4
From: Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
Inhibitory activities of TAS-115 and pazopanib on c-MET, PDGFRα and their downstream effectors in vitro. a Yamato-SS cells (c-MET-dependent SS cells) were treated with 0.1 μM TAS-115 or pazopanib or control (0.1% DMSO) for 3 h. b Yamato-SS cells were treated with 0.001–20 μM of pazopanib or control (0.1% DMSO) for 3 h. c SYO-1 and HS-SY-II (PDGFRα-dependent) SS cells were treated with 10-μM TAS-115 or pazopanib or control (0.1% DMSO) for 3 h, followed by an additional treatment with rhPDGF-BB at a concentration of 10 ng/ml for the last 15 min